Results · Apr-Jun 2026 · filed 7 Aug 2026
Emmessar Biotech & Nutrition Q1 FY27 results
Sales fell 36% to ₹0.06 crore from ₹0.09 crore in Apr-Jun 2025.
Operating profit was −₹0.35 crore, an operating margin of −594.9% (down 296.0 points from a year ago).
Net profit fell 23% to ₹0.13 crore from ₹0.17 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −36%, net profit +285%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 0.1 | 0.1 | −36% |
| Operating profit (EBITDA) | -0.4 | -0.3 | n/m |
| Operating margin | −594.9% | −298.9% | −296.0 pts |
| Net profit | 0.1 | 0.2 | −23% |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
Filings that week
- 8 Aug 2026Newapaper Add
- 7 Aug 2026Unaudited Financial Results For The Quarter Ended June 30, 2026
- 7 Aug 2026Board Meeting Outcome for For Unaudited Financial Results For The Quarter Ending June 30, 2026
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.